Cellectar Biosciences, Inc. (CLRB) Discusses Scientific Rationale and Potential of Phospholipid Ethe

Cellectar Biosciences, Inc. (CLRB) Q2 2026 Earnings Call Transcript

On Thursday, Cellectar Biosciences (NASDAQ:CLRB) discussed second-quarter financial results during i

Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Applicati

Cellectar Biosciences (NASDAQ:CLRB) reported quarterly losses of $(0.57) per share which missed the

Cellectar Biosciences, Inc. (NASDAQ: CLRB - Get Free Report) has been given an average rating of "Mo

FLORHAM PARK, N.J., July 30, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a

Demonstrated Favorable Safety Profile and Preliminary Clinical Activity in Relapsed/Refractory Multi

Demonstrated Favorable Safety Profile and Preliminary Clinical Activity in  Relapsed/Refractory Mult

Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysi

Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysi

https://www.sec.gov/Archives/edgar/data/1279704/000110465926063918/tm2614975d1_s1.htm

Ladenburg Thalmann analyst Kevin DeGeeter assumes Cellectar Biosciences (NASDAQ:CLRB) with a Buy

Cellectar Biosciences, Inc. (CLRB) Q1 2026 Earnings Call Transcript

Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström M

Cellectar Biosciences (NASDAQ:CLRB) reported quarterly losses of $(1.33) per share which beat the an

FLORHAM PARK, N.J., May 11, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a l

Cellectar Biosciences (CLRB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism

Cellectar Biosciences Inc (NASDAQ:CLRB) shares are down during Wednesday's premarket session after t

Cellectar shares slip premarket after rally as CLOVER WaM data, financing plans, and technical signa

US stocks rise, Nasdaq gains 1%. Dow up 0.57%, Nasdaq up 1.03%, S&P 500 up 0.84%. Materials up 2

US stocks rise, Dow gains 300 points. Materials jump 1.8%, real estate falls 0.2%. Pfizer's Q1 e

Cellectar Biosciences, Inc. (NASDAQ:CLRB) shares are up during Tuesday's trading session as the comp

Cellectar releases Phase 2b CLOVER WaM data showing strong response rates and durability, alongside

PINS: 19% | Pinterest shares are trading higher after the company reported better-than-expected Q1 f

83.6% ORR and 61.8% MRR achieved in heavily pretreated population with median duration of response o

83.6% ORR and 61.8% MRR achieved in heavily pretreated population with median duration of response o

Oversubscribed Financing Led by Nantahala Capital with Participation from Balyasny Asset Management,

Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused o

Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused

Study will evaluate tumor-specific uptake, safety, tolerability, and preliminary efficacy signals of

Maxim Group analyst Jason McCarthy upgrades Cellectar Biosciences (NASDAQ:CLRB) from Hold to Buy

Cellectar Biosciences, Inc. (CLRB) Q4 2025 Earnings Call Transcript

On track to submit Conditional Marketing Authorization for iopofosine I 131 to European Medicines Ag